Loading
A phase 3 trial of Sintilimab in colorectal cancer, run by Innovent Biologics (Suzhou) Co. Ltd., active and no longer recruiting.
A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer is a phase 3 interventional study registered as NCT05890742 by Innovent Biologics (Suzhou) Co. Ltd., with 453 participants enrolled, started 2023-05-25 and due to reach its primary completion in 2028-04-15. Interventions recorded: Sintilimab, IBI310&Sintilimab and Radical surgery.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Sintilimab, Monoclonal antibodies, Immune checkpoint inhibitors and the tag pipeline.
Shares Making microsatellite-stable colorectal cancer immunotherapy-responsive, Mismatch-repair deficient (MSI-high) colorectal cancer, Colorectal cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colorectal cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colorectal cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colorectal cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colorectal cancer and the tag pipeline.
Shares Colorectal cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colorectal cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/